Health
Anti-cancer drug’s mode of operation deciphered – EurekAlert
Freiburg researchers show how the membrane protein CD20 keeps the immune system’s antibody-producing cells in check.
IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane.
view more
Credit: Illustration: Julia Jullesova
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients…
-
General20 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business19 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General21 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General22 hours agoAlbanese beats drum on economy as trade clouds gather